Immunoglobulins that bind to the human Vγ9Vδ2 T cell receptor

Immunoglobulin molecules with defined CDR regions are developed to modulate Vγ9Vδ2 T cell activation and reactivity, addressing overstimulation issues and enabling targeted medical treatments and diagnostics.

JP7583130B2Active Publication Date: 2024-11-13LAVA THERAPEUTICS BV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023140495
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2014-04-10
Filing Date
2023-08-30
Publication Date
2024-11-13
Estimated Expiration
2035-04-10

AI Technical Summary

Technical Problem

There is a need for agents that can selectively bind to Vγ9Vδ2 T cells to modulate their activation or reactivity, as overstimulation or unintentional activation of these cells can lead to adverse effects in certain diseases or medical treatments, while also requiring agents that can label or identify these cells for diagnostic purposes.

Method used

Development of immunoglobulin molecules, such as single domain antibodies, that specifically bind to the Vγ9Vδ2 T cell receptor with defined CDR1, CDR2, and CDR3 regions, allowing for modulation of Vγ9Vδ2 T cell activation or reactivity, and can be used in medical treatments or assays.

Benefits of technology

The immunoglobulin molecules effectively block or activate Vγ9Vδ2 T cells as needed, reducing unwanted activation, enhancing their antitumor activity, and facilitating their selective identification and isolation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583130000009
    Figure 0007583130000009
  • Figure 0007583130000010
    Figure 0007583130000010
  • Figure 0007583130000011
    Figure 0007583130000011
Patent Text Reader

Abstract

To provide, among others, agents that can bind to Vγ9Vδ2 T cells, and agents that can block phosphoantigen activation of Vγ9Vδ2 T cells or can activate Vγ9Vδ2 T cells.SOLUTION: The invention is in the field of medicine and relates to immunology, and relates in particular to human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules. Human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and / or useful in assays with human Vγ9Vδ2 T cells, where human Vγ9Vδ2 T cells may be modulated.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention is in the medical field and relates to immunology. The present invention relates to immunoglobulins that bind to T cells. In particular, the present invention relates to immunoglobulins that bind to the human Vy9V52 T cell receptor. The present invention provides immunoglobulin molecules such as antibodies, single chain antibodies or single domain antibodies that bind to the human Vy9V52 T cell receptor, and human Vy9V52 T cells can be modulated. [Background technology]

[0002] The majority of human adult gamma delta peripheral blood lymphocytes (PBLs) express T cell receptors (TCRs) that contain Vgamma9 and Vdelta2 regions. Vgamma9Vdelta2 T cells can respond to a wide range of pathogens and tumor cells. This broad reactivity is understood to be mediated by phosphoantigens that can specifically activate this T cell subset in a TCR-dependent manner. The broad antibacterial and antitumor reactivity of Vgamma9Vdelta2 T cells suggests a direct involvement in the immune control of cancer and infectious diseases. In addition to fighting disease, Vgamma9Vdelta2 T cells may be overstimulated or unintentionally activated in some diseases or medical treatments. [Prior art documents] [Non-patent literature]

[0003] [Non-Patent Document 1] Sambrook et al., Molecular Cloning.A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989 [Non-Patent Document 2] Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1987 [Non-Patent Document 3] Methods in Enzymology, Academic Press, San Diego [Non-Patent Document 4] COMPUTATIONAL MOLECULAR BIOLOGY, edited by Lesk, AM, Oxford University Press, New York, 1988. [Non-Patent Document 5] BIOCOMPUTING: INFORMATICS AND GENOME PROJECTS, edited by Smith, DW, Academic Press, New York, 1993. [Non-Patent Document 6] COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, Griffin, AM and Griffin, HG, eds., Humana Press, New Jersey, 1994 [Non-Patent Document 7] SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, 1987 [Non-Patent Document 8] SEQUENCE ANALYSIS PRIMER; edited by Gribskov, M. and Devereux, J., M Stockton Press, New York, 1991 [Non-Patent Document 9] Carillo, H. and Lipton, D., SIAM J. Applied Math (1988) 48: 1073 [Non-Patent Document 10] GUIDE TO HUGE COMPUTERS, edited by Martin J. Bishop, Academic Press, San Diego, 1994 [Non-Patent Document 11] Devereux, J. et al., Nucleic Acids Research (1984) 12(1):387 [Non-Patent Document 12] Atschul, SF et al., J. Molec. Biol. (1990) 215:403 [Non-Patent Document 13] Albert L. Lehninger, Principles of Biochemistry, pp. 793-800 (Worth Pub. 1982) [Non-Patent Document 14] Claudio Tripodo et al., Gamma delta T cell lymphomas Nature Reviews Clinical Oncology 6, pp. 707-717 (December 2009) [Non-Patent Document 15] Spinelli S et al., Biochemistry 2000;39:1217-1222 [Non-Patent Document 16] Schneiders FL et al., Clin Immunol 2012;142:194-200 [Non-Patent Document 17] Scholten KB et al., Clin Immunol 2006;119:135-45 [Non-Patent Document 18] Allison TJ et al., Nature 2001; 411:820-4 [Non-Patent Document 19] Davodeau F et al. Eur J Immunol 1993; 23:804~8 [Non-Patent Document 20] Roovers RC et al. Cancer Immunol Immunother. 2007;56:303-17 [Non-Patent Document 21] Hoogenboom et al., Nucleic Acids Res 1991 Summary of the Invention [Problem to be solved by the invention]

[0004] Thus, agents capable of activating Vy9V52 T cells may be useful in the treatment of infectious diseases or cancer, as they may promote the reactivity of Vy9V52 T cells against pathogens or infected cells or cancer. Furthermore, agents that block Vy9V52 T cell activation may be useful in diseases or medical treatments where it is advantageous to reduce Vy9V52 T cell activation, i.e. where Vy9V52 T cells are overstimulated or unintentionally activated. Finally, agents that can bind to Vy9V52 T cells but do not affect Vy9V52 T cell activation (phosphoantigen) are useful for labeling cells, e.g., for selecting or identifying Vy9V52 T cells. Thus, there is a need in the art to provide agents that can bind to Vy9V52 T cells and agents that can block phosphoantigen activation of Vy9V52 T cells or activate Vy9V52 T cells. [Means for solving the problem]

[0005] The present invention now provides novel agents capable of binding to Vy9V52 T cells. The agents provided are immunoglobulins. The immunoglobulins provided bind to the Vy9V52 T cell receptor. Surprisingly, it was found that the immunoglobulins provided by the present invention have a significant sequence identity. Thus, in a first aspect of the present invention, a human Vy9V52 T cell receptor binding immunoglobulin molecule is provided, comprising a CDR1 region and a CDR2 region, An immunoglobulin molecule is provided, wherein the CDR1 region comprises an amino acid sequence having at least 40% sequence identity with the amino acid sequence GRTFSNYAMG of SEQ ID NO: 31 and the CDR2 region comprises an amino acid sequence having at least 60% sequence identity with the amino acid sequence AISWSGGSTYYADSVKG of SEQ ID NO: 32, and preferably the immunoglobulin molecule is a single domain antibody.

[0006] Furthermore, such immunoglobulins comprise a CDR3 region, which contributes to Vy9V52 T cell receptor binding and may influence the action of the immunoglobulin molecule. Without being bound by theory, this indicates that the CDR3 sequence may be related to the functionality of the immunoglobulin molecule, i.e. the type of modulation, such as blocking Vy9V52 T cell activation, inducing Vy9V52 T cell activation or neither blocking nor inducing Vy9V52 T cell activation. The immunoglobulins of the invention are particularly for medical treatments and assays involving Vy9V52 T cells.

[0007] Preferably, the immunoglobulin molecule according to the invention comprises a CDR3 region, which comprises an amino acid sequence selected from the group consisting of the amino acid sequences SEQ ID NO: 3, 6, 9, 11, 14, 17, 20, 22, 25, 27, 29, 30, 33, 35, 37, 40, 43 and 46. These CDR3 regions in combination with the CDR1 and CDR2 sequences provide the binding and function detailed below. [Brief description of the drawings]

[0008] [Figure 1] Alignment of VHH sequences showing the framework regions (1, 2, 3 and 4) and CDR1, CDR2 and CDR3. The code of each VHH is also shown (i.e. 5C7 is the sequence of VHH 5C7). [Diagram 2] 3: VHH 5E7 and VHH 6F6 do not activate Vy9V52 T cells. Data show the relative expression of the activation marker CD25, the proinflammatory cytokine IFN-γ and the cytotoxic molecule Granzyme B by healthy donor-derived Vy9V52 T cells compared to positive control (phosphoantigen (pAg+) expressing HeLa cells). [Diagram 3]Figure 3: VHH 5E7 neutralizes phosphoantigen-induced activation of healthy donor-derived Vy9V52 T cells. A representative example using VHH 5E7 shows a dose-dependent neutralization of phosphoAg-induced Vy9V52 T cell activation, whereas a non-specific VHH (negative control) failed to neutralize phosphoAg-induced Vy9V52 T cell activation. The vertical axis shows Vy9V52 T cell activation as assessed by CD25 expression, and the horizontal axis shows different VHH concentrations. Stimulation of Vy9V52 T cells was performed using phosphoantigen-expressing HeLa cells, generated by pre-treating HeLa cells with increasing doses of the aminobisphosphonate pamidronate (which increases the levels of phosphoantigen expression by HeLa cells). [Figure 4] Figure 2: VY9V52 TCR specific VHHs are able to induce activation and cytokine production in healthy donor-derived VY9V52 T cells. Data show the relative expression of the activation marker CD25 and the proinflammatory cytokine IFN-γ by healthy donor-derived VY9V52 T cells compared to positive control [phosphoantigen (pAg+) expressing HeLa cells; normalized to 1] and negative control VHHs. Each bar represents an individual VY9V52 TCR specific VHH, with individual VHHs differing in their ability to induce activation and cytokine production in VY9V52 T cells. [Diagram 5] Figure 3: Dose-dependent activation of healthy donor-derived Vy9V52 T cells. Data show change in CD25 expression (MFI) 24 hours after stimulation with increasing concentrations (10-100-500 nM) of either non-activating or activating anti-Vy9V52 TCR VHHs. [Figure 6]Figure 2: VY9V52 TCR specific VHH can promote tumor cell death when fused to a tumor antigen specific VHH as a bispecific molecule. Representative example of an experiment where VY9V52 T cells were co-cultured overnight with the tumor cell line A431 in the presence (with) or absence (w / o) of a bispecific nanobody construct consisting of a tumor antigen specific VHH fused to an activating anti-VY9V52 TCR VHH. Data show CD25 expression (activation) and CD107a expression (degranulation) of VY9V52 T cells and 7AAD+ tumor cells (indicating tumor cell death). [Figure 7] Figure 2: T cell receptor Vy9 and / or V52 binding specificity as measured using flow cytometry: Representative flow cytometry histograms show binding of Vy9V52 TCR specific VHHs (open histograms) and negative control VHHs (coloured histograms) to Vy9V52 TCR expressing cells. [Figure 8] Figure 1: Clone VHH 5C7 does not activate healthy donor-derived Vy9V52 T cells or neutralize phosphoantigen-induced activation of healthy donor-derived Vy9V52 T cells. Representative examples demonstrate the lack of inhibitory or activating effect of VHH 5C7 on phosphoAg-induced Vy9V52 T cell activation. The vertical axis shows Vy9V52 T cell activation as assessed by CD25 expression, and the horizontal axis shows the various VHH concentrations. Stimulation of Vy9V52 T cells was performed using phosphoantigen-expressing HeLa cells, generated by pre-treating HeLa cells with increasing doses of the aminobisphosphonate pamidronate (which increases the levels of phosphoantigen expression by HeLa cells). [Figure 9]Schematic diagram of immunoglobulins: A) a human antibody consisting of two heavy and two light chains; B) a single chain antibody (or heavy chain only antibody) consisting of two single chains (or two heavy chains) that can dimerize via disulfide bridges, each chain containing a variable domain. Such a single chain antibody (or heavy chain only antibody) may be a llama antibody; C) a single domain antibody, which comprises for example one variable antibody domain of a single chain antibody (or heavy chain only antibody). A single domain antibody may consist of only the binding region as depicted. The variable domains are shown in grey and the constant regions in white. The variable domain of the light chain is shown in black. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Definition: In the following description and examples, a number of terms are used. In order to provide a clear and consistent understanding of the specification and claims and clauses, including the scope to be given to such terms, the following definitions are provided. Unless otherwise defined herein, all technical and scientific terms used have the same meaning as commonly understood by those skilled in the art to which this invention belongs. The disclosures of all publications, patent applications, patents and other references are incorporated herein in their entirety by reference.

[0010] The method of carrying out the conventional techniques used in the method of the present invention will be clear to those skilled in the art. Conventional techniques in molecular biology, biochemistry, computational chemistry, cell culture, recombinant DNA, bioinformatics, genomics, sequencing and related fields are well known to those skilled in the art and are discussed, for example, in the following references: Sambrook et al., Molecular Cloning. A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1987 and periodic revisions, and the series Methods in Enzymology, Academic Press, San Diego.

[0011] In this document and its claims and clauses, the verb "comprise" and its conjugations are used in an open-ended sense to mean that items following the word are included but not items not specifically mentioned are excluded. This encompasses the verbs "consisting essentially of" and "consisting of."

[0012] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. For example, as used above, a method for the isolation of "a" DNA molecule also includes the isolation of a plurality of molecules (e.g., tens, hundreds, thousands, tens of thousands, hundreds of thousands, millions, tens of millions, hundreds of thousands, millions, or more molecules).

[0013] Aligning and alignment: The terms "aligning" and "alignment" refer to the comparison of two or more amino acid sequences based on the presence of short or long stretches of matching or similar amino acids. As will be explained further below, several methods are known in the art for the alignment of amino acid sequences. The terms "aligning" and "alignment" also refer to the comparison of two or more nucleotide sequences based on the presence of short or long stretches of matching or similar nucleotides. As will be explained further below, several methods are known in the art for the alignment of nucleotide sequences.

[0014] "Gene expression" or "protein expression" refers to the process by which a DNA region operably linked to appropriate regulatory regions, particularly a promoter, is transcribed into RNA that can be translated by the cellular machinery into a protein or peptide (or active peptide fragment) encoded by the nucleotide sequence, or which is itself active (e.g., in post-transcriptional gene silencing or RNAi).

[0015] As used herein, the term "operably linked" refers to linking polynucleotide elements in a functional relationship. A nucleic acid is "operably linked" when it is inserted into a functional relationship with another nucleic acid sequence. For example, a promoter or rather a transcription control sequence is operably linked to a coding sequence if it affects the transcription of the coding sequence. Operatively linked means that the DNA sequences being linked are generally contiguous, and where necessary to join two or more protein coding regions, that the DNA sequences being linked are contiguous and in reading frame.

[0016] The term "genetic construct" refers to a DNA sequence comprising a region to be transcribed into a cellular RNA molecule (e.g., mRNA) (transcriptional region), operably linked with suitable regulatory regions (e.g., promoters). Thus, a genetic construct may comprise several operably linked sequences, such as a promoter, a 5' leader sequence, including, for example, sequences involved in translation initiation, a (protein) coding region, splice donor and acceptor sites, intron and exon sequences, and a 3' non-translated sequence (also known as a 3' untranslated sequence or 3' UTR), including, for example, a transcription termination sequence site.

[0017] "Sequence identity" is the degree of identity of nucleotide or amino acid sequences. Generally, sequences are aligned to obtain the highest degree of correspondence. "Identity" per se has an art-recognized meaning and can be calculated using published techniques. See, e.g., (COMPUTATIONAL MOLECULAR BIOLOGY, edited by Lesk, AM, Oxford University Press, New York, 1988; BIOCOMPUTING: INFORMATICS AND GENOME PROJECTS, edited by Smith, DW, Academic Press, New York, 1993; COMPUTER ANALYSIS OF SEQUENCE DATA, PART I, edited by Griffin, AM and Griffin, HG, Humana Press, New Jersey, 1994; SEQUENCE ANALYSIS IN MOLECULAR BIOLOGY, von Heinje, G., Academic Press, 1987; and SEQUENCE ANALYSIS PRIMER; edited by Gribskov, M. and Devereux, J., M Stockton Press, New York, 1991). Although there are several methods for determining the identity between two polynucleotide or polypeptide sequences, the term "identity" is well known to those skilled in the art [Carillo, H. and Lipton, D., SIAM J. Applied Math (1988) 48: 1073]. Commonly used methods for determining identity or similarity between two sequences include, but are not limited to, those disclosed in GUIDE TO HUGE COMPUTERS, edited by Martin J. Bishop, Academic Press, San Diego, 1994, and Carillo, H. and Lipton, D., SIAM J. Applied Math (1988) 48: 1073. Methods for determining identity and similarity are categorized in computer programs.Preferred computer program methods for determining identity and similarity between two sequences include, but are not limited to, the GCS program package [Devereux, J. et al., Nucleic Acids Research (1984) 12(1):387], BLASTP, BLASTN, FASTA [Atschul, SF et al., J. Molec. Biol. (1990) 215:403].

[0018] As an illustration, an amino acid sequence having at least, for example, 70% "sequence identity" with the reference amino acid sequence of SEQ ID NO: 31 is intended to mean that the amino acid sequence corresponds to the reference sequence, except that the polypeptide sequence may contain up to 3 amino acid modifications for each of the 10 amino acids of the reference amino acid sequence of SEQ ID NO: 31. Thus, the percentage of identity of an amino acid sequence to a reference amino acid sequence should be calculated over the full length of the reference amino acid sequence. In other words, to obtain an amino acid sequence that contains at least 70% identity with the reference amino acid sequence, up to 30% of the amino acid residues in the reference sequence may be removed or replaced with another amino acid, or several amino acids up to 30% of the total amino acid residues in the reference sequence may be inserted into the reference sequence. Such modifications of the reference sequence may occur at the amino or carboxy terminal position of the reference amino acid sequence, or may occur anywhere between the amino and carboxy terminal positions, either individually between the residues in the reference sequence or scattered in one or more contiguous groups within the reference sequence.

[0019] A "nucleic acid" or "nucleic acid sequence" according to the invention may comprise any polymer or oligomer of pyrimidine and purine bases, preferably cytosine, thymine and uracil, and adenine and guanine, respectively [see Albert L. Lehninger, Principles of Biochemistry, pp. 793-800 (Worth Pub. 1982), which is incorporated herein by reference in its entirety for all purposes]. The invention contemplates any deoxyribonucleotide, ribonucleotide or peptide nucleic acid building block and any chemical modifications thereof, such as methylated, hydroxymethylated or glycosylated forms of these bases, and the like. The polymer or oligomer may be heterogeneous or homogeneous in composition and may be isolated from naturally occurring sources or may be artificially or synthetically produced. Furthermore, the nucleic acid may be DNA or RNA or a mixture thereof and may exist permanently or transiently in single-stranded or double-stranded form, including homoduplexes, heteroduplexes and hybrid states.

[0020] As used herein, the term "cancer" refers to or describes a physiological condition in mammals that is generally characterized by unregulated cell proliferation. Examples of cancer include, but are not limited to, breast cancer, colon cancer, lung cancer, prostate cancer, hepatocellular carcinoma, gastric cancer, pancreatic cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, urinary tract cancer, thyroid cancer, kidney cancer, carcinoma, skin cancer, blood cancer, leukemia, melanoma, head and neck cancer, and brain cancer. As used herein, "cancer" is also referred to as malignant neoplasm.

[0021] The term "amino acid sequence" or "protein" or "peptide" refers to a molecule consisting of a chain of amino acids, regardless of a specific mode of action, size, three-dimensional structure or origin. Thus, "fragments" or "portions" thereof may still be referred to as "amino acid sequences" or "proteins" or "peptides". An "isolated amino acid sequence" is used to refer to an amino acid sequence that is no longer in its original natural environment, for example in vitro or in a recombinant bacterial or human host cell.

[0022] "T cells" or "T lymphocytes" belong to a group of white blood cells called lymphocytes, which are involved in cell-mediated immunity. T cells arise from hematopoietic stem cells in the bone marrow, mature in the thymus (i.e., the place of origin of T), and acquire their full function in peripheral lymphoid tissues. During the development of T cells, CD4 - CD8 - T cells (negative for both CD4 and CD8 co-receptors) are committed to either an αβ or γδ fate as a result of early β or δ TCR gene rearrangements. Cells that undergo early β chain rearrangement express a pre-TCR structure composed of an intact β chain and a pre-TCR α chain on the cell surface. Such cells express CD4 + CD8 + CD4 T cells that have successfully completed γ gene rearrangement prior to β gene rearrangement switch to a state in which they rearrange the TCR α chain locus and express mature αβ TCR on their surface. - CD8 - T cells express functional γδ TCR and are CD4 - CD8 -[Claudio Tripodo et al., Gamma delta T cell lymphomas Nature Reviews Clinical Oncology 6, 707-717 (December 2009)]. The T cell receptor associates with the CD3 protein complex. Mature T cells, i.e., T cells expressing αβTCR or γδTCR, express the T cell receptor complex on the cell surface. γδ T cells, which constitute about 1-5% of the total population of T cells in human peripheral blood, can be further divided into subpopulations. A subpopulation of γδ T cells constitutes Vγ9Vδ2 T cells, which express the Vγ9Vδ2 TCR. Within the extracellular domain of the T cell receptor are the complementarity determining regions (CDR1, CDR2, CDR3). These regions are generally the most variable domains and contribute significantly to the diversity among TCRs. The CDR regions are constructed during T-cell development, where so-called variable (V), diversity (D) and joining (J)-gene segments are randomly combined to form different TCRs.

[0023] "Vγ9Vδ2 T cells" are cells that can be functionally defined in that they are specifically and rapidly activated by a series of non-peptidic phosphorylated isoprenoid precursors, collectively referred to as phosphoantigens. Phosphoantigens are produced by virtually all living cells. The most common phosphoantigens found in animal and human cells, including cancer cells, are isopentenyl diphosphate (IPP) and its isomer, dimethylallyl diphosphate (DMAPP). IPP is a metabolite from the mevalonate pathway. (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP or HMB-PP) is an intermediate in the non-mevalonate pathway of isoprenoid biosynthesis. HMBPP is an essential metabolic product in most pathogenic bacteria, including Mycobacterium tuberculosis, and parasitic protozoans such as Plasmodium falciparum (which causes malaria) and Toxoplasma gondii. Activation of Vy9V52 T cells includes clonal expansion, cytotoxic activity and expression of cytokines. "Vy9V52 T cells" are also defined by expression of the Vy9V52 T cell receptor. For example, cells may be selected using antibodies specific for the Vy9V52 T cell receptor, such as those described below. These selected cells undergo rearrangement of gamma and delta genes to encode the Vy9 and V52 T cell receptor chains. From such selected cells, the nucleic acid (or amino acid) sequences corresponding to the Vy9 and V52 T cell receptor chains may be determined.

[0024] The skilled artisan will be able to appropriately select and / or identify cell populations characterized by the expression of antigens or receptors on the surface of the cells, such as those described throughout this specification. Of course, with respect to the expression on the surface of the cells, such as CD3, CD4, CD8, CD25, CD69, γδTCR and Vγ9Vδ2 TCR, this is generally done in a population of cells in which a portion of the cells have a much higher expression level compared to cells with a lower level of expression of the antigen or receptor. Thus, the terms positive or negative should be understood to be relative, i.e., positive cells have a much higher expression level compared to negative cells. Thus, cells that are negative in this sense may still have a detectable expression level. The expression on the surface of the cells may be analyzed using fluorescence-activated cell sorting (FACS), and many specific antibodies against, for example, CD3, CD4, CD8, CD25, CD69, γδTCR, Vγ9 TCR chain and Vδ2 TCR chain are commercially available and suitable for such FACS analysis, such as those described and available in the examples. Such specific antibodies are immunoglobulins that bind to their respective antigens or receptors. Thus, Vy9V52 T cells can also be defined and selected as positive for Vy9V52 TCR in FACS. Antibodies suitable for FACS or similar separation techniques (such as antibodies coupled to magnetic beads) are widely available. Conditions are chosen, such as those provided by antibody manufacturers, that allow the selection of negative and / or positive cells. Examples of antibodies that may be suitable for the selection of Vy9V52 T cells or artificial Vy9V52 T cells, e.g. available from BD Pharmingen (BD, 1 Becton Drive, Franklin Lakes, NJ, USA), are Vy9-PE (clone B3, number 555733), V52-FITC (clone B6, number 555738), γδTCR-APC (clone B1, number 555718) or, e.g. available from Beckman Coulter, pan-γδTCR-PE (clone IMMU510, number IM1418U).Examples of antibodies that may be suitable for detecting CD25 and CD69 are CD25-PE (clone M-A251, no. 555432) and CD69-FITC (clone L78, no. 347823) available from BD Pharmingen.

[0025] Detailed description of the invention: In a first aspect of the invention there is provided a human Vy9V52 T cell receptor binding immunoglobulin molecule comprising a CDR1 region and a CDR2 region, wherein the CDR1 region comprises an amino acid sequence having at least 40% sequence identity with the amino acid sequence GRTFSNYAMG of SEQ ID NO: 31, An immunoglobulin molecule is provided, wherein the CDR2 region comprises an amino acid sequence having at least 60% sequence identity with the amino acid sequence AISWSGGSTYYADSVKG of SEQ ID NO: 32, and preferably, the immunoglobulin molecule is a single domain antibody.

[0026] A human Vy9V52 T cell receptor binding immunoglobulin molecule according to the invention is an immunoglobulin molecule that binds to the Vy9V52 T cell receptor, such as for example those defined by the amino acid sequences of the Vy9 and V52 T cell receptor chains given in SEQ ID NOs: 71 and 72. Binding to such a T cell receptor can be detected for example by FACS analysis, such as that described in the Examples section. For example, cells expressing a Vy9V52 T cell receptor, such as SEQ ID NOs: 71 and 72, are contacted with either a control immunoglobulin molecule or an immunoglobulin molecule that binds to the Vy9V52 T cell receptor. Alternatively, Vy9V52 T cells from a healthy human donor may be contacted with either a control immunoglobulin molecule or an immunoglobulin molecule that binds to the Vy9V52 T cell receptor as described in the Examples. The amount of immunoglobulin bound to the cells is increased when the specific immunoglobulin molecule is compared to a control immunoglobulin molecule that does not bind to the Vy9V52 T cell receptor (see for example Figure 7). Human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules according to the present invention can be defined as immunoglobulins that have a minimum of a two-fold increase in mean fluorescence intensity (MFI) compared to a control immunoglobulin when measured, for example, by flow cytometry. The MFI is the average of the fluorescence intensity in the selected fluorescence channel (FITC, PE, PerCP, etc.). A single domain antibody (or VHH, nanobody) against the azo dye Reactive Red 6 (RR6) may be used as a negative control antibody (Spinelli S et al., Biochemistry 2000;39:1217-1222). Thus, the skilled artisan can appropriately select suitable conditions for measuring the binding of an immunoglobulin molecule to the Vγ9Vδ2 T cell receptor. Immunoglobulin binding can be expressed in terms of specificity and affinity. Specificity determines which antigen or its epitope an immunoglobulin molecule binds to.

[0027] "Immunoglobulin molecule" (abbreviated as "Ig") as used herein is well known in the art and includes the term "antibody". The term "immunoglobulin" as used herein refers to any polypeptide comprising an antigen-binding site with complementarity determining regions (CDRs). The term includes, but is not limited to, antibodies, monoclonal antibodies, monospecific antibodies, multispecific antibodies, humanized antibodies, chimeric antibodies, human antibodies, single chain antibodies, heavy chain only antibodies, llama antibodies, single domain antibodies and nanobodies (e.g., VHHs). The term "immunoglobulin molecule" may also include immunoglobulin fragments such as Fab, F(ab')2, Fv, scFv, Fd, dAb and other antibody fragments or other constructs containing CDRs that retain antigen-binding function. Generally, such fragments contain the antigen-binding domain. The immunoglobulin molecule or fragment thereof may be of any known antibody isotype and their conformation, for example IgA such as IgA1 or IgA2, IgD, IgE, IgG such as IgG1, IgG2a, IgG2b, IgG3, IgG4 or IgM class, or may constitute a mixture thereof in any combination, for example a mixture of antibodies of IgG1 and IgG2a class.

[0028] Immunoglobulins are immune system related proteins. Human antibodies consist of four polypeptides, two heavy and two light chains linked together to form a "Y" shaped molecule (see Figure 9A). The amino acid sequence at the tip of the "Y" varies widely between different antibodies. Each tip has a specificity for binding to an antigen. The variable region of a human antibody includes the ends of the light and heavy chains, i.e. the variable domains of the light and heavy chains. The constant region determines, for example, the mechanism used to activate the immune system.

[0029] Antibodies are divided into five major classes, IgM, IgG, IgA, IgD and IgE, based on their heavy chain constant region structure and immune function. Subclasses of heavy chains are also known. For example, human IgG heavy chains can be any of the IgG1, IgG2, IgG3 and IgG4 subclasses.

[0030] Each chain, i.e., immunoglobulin molecule, has a variable domain. The variable domain of an immunoglobulin molecule is subdivided into hypervariable (HV) and framework (FR) regions. HV regions have a high ratio of different amino acids at a given position relative to the most common amino acid at that position. Hypervariable regions are also called complementarity determining regions (CDRs). Immunoglobulin molecules have three complementarity determining regions (CDR1, CDR2, and CDR3). Four framework regions, which have a much less variable amino acid sequence, separate each CDR region. The CDR regions can directly bind to an antigen, such as the Vy9V52 T cell receptor (see, for example, FIG. 1, where the framework and CDR regions of selected VHHs are shown). The framework regions form a beta sheet structure that serves as a scaffold to position the CDR regions to contact the antigen.

[0031] Llama antibodies consist of two heavy chains (see Figure 9B). Each heavy chain is an immunoglobulin molecule with one variable domain. Such antibodies are called single-chain antibodies, i.e., they contain one type of chain. Such antibodies are sometimes called heavy-chain-only antibodies.

[0032] Single domain antibodies are immunoglobulin molecules that contain one monomeric variable domain (see FIG. 9C). Thus, single domain antibodies contain one CDR1, one CDR2 and one CDR3. Single domain antibodies may be derived from single chain antibodies (or heavy chain only antibodies). Like complete antibodies, single domain antibodies can selectively bind to a specific antigen. Single domain antibodies may contain only the variable domain of an immunoglobulin chain with CDR1, CDR2 and CDR3 and framework regions, and such antibodies may also be called VHH or nanobodies. Nanobodies, with a molecular weight of only about 12-15 kDa, are much smaller than common antibodies (150-160 kDa) that are composed of two heavy chains and two light chains.

[0033] CDR1, CDR2 and CDR3 sequences may be exchanged between species. For example, CDR sequences from a llama immunoglobulin molecule may be selected and exchanged with CDR sequences of a human immunoglobulin molecule to obtain a human immunoglobulin molecule with the specificity derived from the llama CDR sequences. This may be advantageous as the human sequences may be less immunogenic to humans compared to the original llama framework sequences. Such an exchange of CDR sequences is known as humanization. Thus, immunoglobulin molecules, single chain antibodies and single domain antibodies according to the invention may have human-derived or llama-derived immunoglobulin sequences, with CDR1, CDR2 and CDR3 sequences replaced with CDR sequences according to the invention to provide human Vy9V52 T cell receptor binding. For example, a human single chain antibody may comprise a sequence corresponding to a human heavy chain sequence but mutated, e.g. with the CH1 domain removed, such that a llama-like single chain antibody is formed (see e.g. FIG. 9B), with the CDR regions of said human heavy chain sequence replaced by CDR sequences according to the invention. Thus, a human immunoglobulin, human single chain antibody or human single domain antibody refers to the origin of the framework and / or constant regions, and not to the origin of the CDR1, CDR2 and CDR3 regions of the invention.

[0034] As described in the Examples section, human Vy9V52 T cell receptor binding immunoglobulin molecules were selected by immunizing Llama glama with human donor-derived Vy9V52 T cells and using a strategy involving phage display. The selected VHH sequences were sequenced and listed in Table 3 and shown in Figure 1. The CDR1, CDR2 and CDR3 regions of the selected VHHs are listed below in Table 1. Each of the CDRs is also listed in Table 3 with the corresponding SEQ ID NO.

[0035] [Table 1]

[0036] The immunoglobulins selected by the inventors to bind to the human Vy9V52 T cell receptor surprisingly had significant sequence identity with respect to CDR1 and CDR2. Without being bound by theory, such CDR1 and CDR2 sequences contribute substantially to the binding of the Vy9V52 T cell receptor. More diversity was found with respect to the CDR3 region, which, without being bound by theory, may be related to the functionality of the immunoglobulin molecule, i.e. the type of modulation, such as blocking Vy9V52 T cell activation, inducing Vy9V52 T cell activation or neither blocking nor inducing Vy9V52 T cell activation. Thus, the immunoglobulin molecule comprises a CDR1 region and a CDR2 region, the CDR1 region comprising an amino acid sequence having at least 40% sequence identity with the amino acid sequence GRTFSNYAMG of SEQ ID NO: 31, and the CDR2 region comprising an amino acid sequence having at least 60% sequence identity with the amino acid sequence AISWSGGSTYYADSVKG of SEQ ID NO: 32. Preferably, the CDR2 region comprises an amino acid sequence having at least 70% sequence identity with the amino acid sequence of SEQ ID NO:32.

[0037] Preferably, the immunoglobulin molecule is a single-chain antibody. As mentioned above, the immunoglobulin is derived from llamas. Llamas produce antibodies with a single heavy chain dimerized by disulfide bridges. That is, llama antibodies have two single variable domains from two chains (see Figure 9B).

[0038] In one embodiment, the CDR2 region comprises an amino acid sequence having at least 60% sequence identity with SEQ ID NO: 32 AISWSGGSTYYADSVKG, said amino acid sequence having a T at position 9, an A at position 12 and a V at position 15. When the sequences of the selected CDR2 regions are compared, the amino acids at these positions show no change. Thus, without being bound by theory, these positions appear to be important for binding to the Vy9V52 T cell receptor. It should be understood that the positions mentioned relate to positions in the reference sequence and not to positions in the immunoglobulin molecule as a whole. Thus, the CDR2 region has identical amino acids to SEQ ID NO: 32 at the particular positions.

[0039] As described in the Examples section, the CDR1, CDR2 and CDR3 regions were selected from a llama antibody. Thus, the single chain antibody according to the invention may comprise immunoglobulin molecule sequences from a llama. Of course, in such a llama single chain antibody, the original CDR sequences are replaced with replacement CDR sequences, such as those listed in Table 1, resulting in a llama single chain with the specificity of the replacement CDR sequences. Similarly, the same can be done with human heavy chain sequences. This human single chain antibody has the specificity governed by the replacement CDR sequences. The introduction of CDR1, CDR2 and CDR3 regions into other frameworks, such as human frameworks, into other species, is well known in the art.

[0040] In one embodiment, the single chain antibody is a single domain antibody. A single chain antibody comprises a framework region. Thus, a human single domain antibody may have a human framework region, for example derived from either a human heavy chain and / or a human light chain sequence, and a CDR1, CDR2 and CDR3 sequence according to the invention. A llama single domain antibody has a llama framework region.

[0041] In one embodiment, one or more framework regions are selected from the group of amino acid sequences of SEQ ID NOs: 67 to 70. These framework regions are framework regions from one of the isolated VHH clones. As can be observed, the framework regions of the 20 isolated clones are substantially unchanged.

[0042] In one embodiment, the immunoglobulin molecule, single chain antibody or single domain antibody comprises a CDR3 region, which comprises an amino acid sequence selected from the group consisting of amino acid sequences SEQ ID NO: 3, 6, 9, 11, 14, 17, 20, 22, 25, 27, 29, 30, 33, 35, 37, 40, 43 and 46. These CDR3 regions in combination with the CDR1 and CDR2 sequences provide binding and function as described below.

[0043] In one embodiment, the immunoglobulin molecule, single chain antibody or single domain antibody has a combination of amino acid sequences of the CDR1, CDR2 and CDR3 regions of antibodies such as those listed in Table 1. In one embodiment, the immunoglobulin molecule, single chain antibody or single domain antibody comprises an amino acid sequence selected from the group of amino acid sequences consisting of SEQ ID NOs: 47-66.

[0044] In one embodiment, an immunoglobulin molecule for medical treatment according to the invention as disclosed above is provided. Of course, when a human Vy9V52 T cell receptor binding immunoglobulin molecule binds to a human Vy9V52 T cell in vivo, e.g. in a medical treatment, it may not be desirable for the immunoglobulin molecule to be a fully functional immunoglobulin molecule, since upon binding to the human Vy9V52 T cell it may induce an immune response directed against the human Vy9V52 T cell. Thus, in such a scenario, immunoglobulin molecules that do not have a functional constant region, i.e. where the constant region has been inactivated or removed, are preferred, such as for example nanobodies and VHHs. This may be particularly useful when the action of human Vy9V52 T cells is required in vivo.

[0045] In one embodiment, a nucleotide sequence is provided that encodes an immunoglobulin molecule according to the present invention. The sequences disclosed herein relate to amino acid sequences. Thus, one skilled in the art can provide a nucleotide sequence that appropriately encodes an amino acid sequence, since all that is required is to use a codon table to convert the amino acid sequence to a nucleotide sequence. Such a nucleotide sequence may be used to operably link it with a promoter sequence, a polyA signal, etc., to provide a genetic construct capable of expressing the antibody. Such a genetic construct comprising the nucleotide sequence may be contained within a host cell.

[0046] In one embodiment, there is provided a method for preparing an immunoglobulin molecule according to the invention, comprising the steps of: - culturing a host cell according to the invention which contains a nucleotide sequence encoding an immunoglobulin molecule according to the invention; - expressing an immunoglobulin in a host cell; - obtaining immunoglobulins; A method is provided, comprising:

[0047] Furthermore, the present invention also provides human Vy9V52 T cell receptor binding immunoglobulin molecules that are immunoglobulin molecules that block activation of human Vy9V52 T cells, which is advantageous for conditions and / or treatments in which activation of human Vy9V52 T cells is undesirable.

[0048] Vy9V52 T cells can be strongly and specifically activated by small non-peptidic phosphorylated intermediates called phosphoantigens (pAg) from the mammalian mevalonate pathway or the microbial deoxyxylulose-phosphate pathway. The phosphoantigens can then be specifically recognized by Vy9V52 T cells (leading to activation) by the interaction between pAg and membrane-bound butyrophilin3A1 / CD277 molecules. As shown in this example, Vy9V52 T cell receptor-binding immunoglobulin molecules can block phosphoantigen-induced activation of Vy9V52 T cells.

[0049] Preferably, the human Vy9V52 T cell receptor binding immunoglobulin molecule, wherein the immunoglobulin molecule is an immunoglobulin molecule that blocks activation of human Vy9V52 T cells, is a human Vy9V52 T cell receptor binding immunoglobulin molecule comprising a CDR1 region and a CDR2 region, wherein the CDR1 region comprises an amino acid sequence having at least 40% sequence identity with the amino acid sequence GRTFSNYAMG of SEQ ID NO: 31 and the CDR2 region comprises an amino acid sequence having at least 60% sequence identity with the amino acid sequence AISWSGGSTYYADSVKG of SEQ ID NO: 32, preferably wherein the immunoglobulin molecule is a single chain antibody. In one embodiment, the CDR2 region of said immunoglobulin molecule comprises an amino acid sequence having at least 40% sequence identity with the amino acid sequence AISWSGGSTYYADSVKG of SEQ ID NO: 2 T YY A DS V KG, said amino acid sequence having at least 60% sequence identity with T at position 9, A at position 12 and V at position 15. In another embodiment the immunoglobulin molecule is a single domain antibody, preferably the single domain antibody is derived from a llama single chain antibody or a human single chain antibody. In another embodiment the immunoglobulin molecule is a single chain antibody or a single domain antibody. In yet another embodiment the immunoglobulin molecule or the single chain antibody or the single domain antibody comprises one or more framework regions selected from the group of amino acid sequences of SEQ ID NOs: 67-70.

[0050] In one embodiment, said human Vy9V52 T cell receptor binding immunoglobulin molecule that blocks activation of human Vy9V52 T cells is for use in a medical treatment. In another embodiment, said immunoglobulin molecule is for use in a medical treatment, wherein the medical treatment comprises the use of an inhibitor of the mevalonate pathway, or wherein the medical treatment comprises the treatment of cancer. In another further embodiment, said immunoglobulin molecule is for use in a medical treatment, wherein the medical treatment comprises the treatment of an infectious disease.

[0051] Inhibitors of the mevalonate pathway that act downstream of pAg production include the commonly clinically prescribed aminobisphosphonates, such as pamidronate, alendronate, risedronate, ibandronate and zoledronate. Another class of compounds includes alkylamines, such as isobutylamine, isoamylamine and n-butylamine. Such compounds can be used to treat Paget's disease, osteoporosis, hypercalcemia and to prevent skeletal events in cases of malignant bone metastasis. This leads to intracellular accumulation of the endogenous pAg isopentenyl diphosphate (IPP) and subsequent selective activation and proliferation of Vγ9Vδ2 T cells. Aminobisphosphonate administration is often accompanied by an acute febrile reaction due to this selective activation of Vγ9Vδ2 T cells. This acute phase reaction has a peak onset of 1 day and a median duration of 3 days and consists mainly of fever, chills, flushing, acute musculoskeletal symptoms, pain, general discomfort and localized complaints involving the back, neck, chest or shoulders, nausea, vomiting and diarrhea. Thus, in medical treatment, said human Vy9V52 T cell receptor binding immunoglobulin molecules that block the activation of human Vy9V52 T cells can prevent acute phase reactions induced, for example, by aminobisphosphonate administration in patients with Paget's disease, osteoporosis, bone metastases and hypercalcemia. Furthermore, such immunoglobulin molecules may also be advantageous in the medical treatment of excessive activation of Vy9V52 T cells in vivo, which may occur, for example, during infections where Vy9V52 T cells are overstimulated or chronically stimulated, or in certain cancerous conditions where chronic overactivity of the mevalonate pathway in tumor cells may exhaust Vy9V52 T cells. Such (over)stimulation in a patient can be determined, for example, by measuring an increase in Vy9V52 T cells compared to baseline levels, in combination with upregulation of surface markers such as CD69 (early activation marker) or CD25 (late activation marker) on Vy9V52 T cells, or by measuring supra-normal levels of Vy9V52 T cells, for example where more than 5% of T cells are Vy9V52 T cells.Of course, it is not necessary to measure supernormal levels of Vγ9V52 T cells due to migration of Vγ9V52 T cells from blood to tissues. On the other hand, with long-term overstimulation, Vγ9V52 T cells may not be sufficiently activated, which may also be a sign of overstimulation. Cytokine production (IFN-gamma, TNF-alpha) and cytotoxic granule content can also be measured intracellularly by flow cytometry.

[0052] In a preferred embodiment, said human Vy9V52 T cell receptor binding immunoglobulin molecule that blocks activation of human Vy9V52 T cells is an immunoglobulin molecule comprising a CDR3 region, wherein the CDR3 region comprises an amino acid sequence selected from the group consisting of the amino acid sequences SEQ ID NO: 27 and SEQ ID NO: 30.

[0053] In one embodiment, said human Vy9V52 T cell receptor binding immunoglobulin molecule that blocks activation of human Vy9V52 T cells is used to block activation of human Vy9V52 T cells. According to this embodiment, said immunoglobulin molecule (including single chain or single domain antibodies) is used in assays such as those described in the Examples to block activation.

[0054] The present invention also provides an immunoglobulin molecule that activates human Vy9V52 T cells, i.e. a human Vy9V52 T cell receptor binding immunoglobulin molecule, comprising a CDR1 region and a CDR2 region, wherein the CDR1 region comprises an amino acid sequence having at least 40% sequence identity with the amino acid sequence GRTFSNYAMG of SEQ ID NO: 31 and the CDR2 region comprises an amino acid sequence having at least 60% sequence identity with the amino acid sequence AISWSGGSTYYADSVKG of SEQ ID NO: 32, preferably a single chain antibody. In one embodiment, the CDR2 region comprises an amino acid sequence having at least 40% sequence identity with the amino acid sequence AISWSGGSTYYADSVKG of SEQ ID NO: 33, preferably a single chain antibody. T YY A DS VKG, said amino acid sequence having at least 60% sequence identity with T at position 9, A at position 12 and V at position 15. In another embodiment the immunoglobulin molecule is a single domain antibody, preferably the single domain antibody is a llama single chain antibody or a human single chain antibody. In another embodiment the single chain antibody is a single domain antibody. In a further embodiment the immunoglobulin molecule or single chain antibody or single domain antibody comprises one or more framework regions selected from the group of amino acid sequences of SEQ ID NOs: 67-70.

[0055] Preferably, said immunoglobulin molecule that activates human Vy9V52 T cells comprises a CDR3 region, wherein the CDR3 region comprises an amino acid sequence selected from the group consisting of the amino acid sequences SEQ ID NOs: 6, 9, 11, 14, 17, 20, 22, 25, 29, 33, 35 and 46.

[0056] Current strategies aimed at harnessing Vy9V52 T cells rely on their systemic activation (e.g., by aminobisphosphonates or synthetic phosphoantigens such as BrHPP) or adoptive transfer of, for example, Vy9V52 T cells. These approaches have been shown to be well tolerated by patients and have demonstrated signs of antitumor activity. However, the results are not consistent enough for general clinical application. The strategies presented activate Vy9V52 T cells systemically, but do not specifically recruit these cells to the tumor where they will exert their antitumor effect. Said immunoglobulin molecules, which activate human Vy9V52 T cells and are preferably linked to a drug, can be used to activate Vy9V52 T cells in a clinical setting.

[0057] The immunoglobulin molecule that activates human Vy9V52 T cells is preferably linked to an agent. The agent is preferably an agent that can bind to a target, e.g., a cancer cell or an infected cell, e.g., a virus-infected cell, or a non-host cell, e.g., a bacterium. Preferably, the agent is an immunoglobulin molecule. More preferably, the immunoglobulin molecule is a single chain antibody or a single domain antibody. By linking to an agent, the agent can recruit and activate human Vy9V52 T cells to a site where the action of human Vy9V52 T cells is required, as opposed to systemic activation. For example, the immunoglobulin molecule that activates human Vy9V52 T cells can be linked to a tumor-specific antibody, an antiviral antibody, or an antibacterial antibody. Such a tumor-specific antibody can be any antibody. Such an immunoglobulin molecule linked to another antibody can be called a bispecific antibody. A bispecific antibody may also consist of a first immunoglobulin molecule comprising the CDR1, CDR2 and CDR3 regions according to the invention and being a chain such as that contained in a single chain antibody, where the first immunoglobulin chain is paired with a second immunoglobulin molecule, also being a chain such as that contained in a single chain antibody, where the second immunoglobulin binds to a target. Thus, a bispecific antibody is formed with two chains, each chain having one different binding domain (as shown in FIG. 9B), where one binding domain comprises the CDR1, CDR2 and CDR3 regions according to the invention and the other binding domain binds to a target. The immunoglobulin molecule linked to an agent that activates human Vy9V52 T cells may also be a bispecific antibody comprising two single domain antibodies, where the first single domain antibody comprises the CDR1, CDR2 and CDR3 regions according to the invention and is linked to a second single domain antibody that binds to a target.

[0058] Thus, in one embodiment, said immunoglobulin molecule that activates human Vy9V52 T cells, preferably linked to an agent, is for use in a medical treatment. Preferably, the medical treatment is the treatment of cancer or an infection.

[0059] In another embodiment, there is provided a use of said immunoglobulin molecule that activates human Vy9V52 T cells for activating human Vy9V52 T cells, such use being useful, for example, in assays such as those described in the Examples.

[0060] In another embodiment, said immunoglobulin molecules that activate human Vy9V52 T cells comprise a label. Such immunoglobulin molecules are particularly useful for flow cytometry of cells expressing human Vy9V52 T cell receptors. The immunoglobulin molecules may comprise a tag, e.g. a myc-tag or his-tag or a fluorescent protein sequence as described in the examples, or may be conjugated to a suitable imaging dye. Furthermore, when conjugated to, e.g., magnetic beads, such immunoglobulin molecules can be used to isolate and purify these cells from cell suspensions, including cell suspensions from peripheral blood. Since such immunoglobulins activate human Vy9V52 T cells, these immunoglobulin molecules are particularly useful for selecting these cells while simultaneously activating and expanding the cell population. Thus, there is further provided the use of these immunoglobulin molecules for labeling and / or selecting and activating human Vy9V52 T cells.

[0061] In another aspect of the invention there is provided an immunoglobulin molecule which is a human Vy9V52 T cell receptor binding immunoglobulin molecule which does not block activation of human Vy9V52 T cells and does not activate human Vy9V52 T cells, comprising a CDR1 region and a CDR2 region, wherein the CDR1 region comprises an amino acid sequence having at least 40% sequence identity with the amino acid sequence GRTFSNYAMG of SEQ ID NO: 31 and the CDR2 region comprises an amino acid sequence having at least 60% sequence identity with the amino acid sequence AISWSGGSTYYADSVKG of SEQ ID NO: 32, preferably a single chain antibody. T YY A DS VKG, said amino acid sequence having at least 60% sequence identity with T at position 9, A at position 12 and V at position 15. In another embodiment the immunoglobulin molecule is a single domain antibody, preferably the single domain antibody is a llama single chain antibody or a human single chain antibody. In another embodiment the single chain antibody is a single domain antibody. In yet another embodiment the immunoglobulin molecule or single chain antibody or single domain antibody comprises one or more framework regions selected from the group of amino acid sequences of SEQ ID NOs: 67-70.

[0062] In one embodiment, the immunoglobulin molecule that does not block activation of human Vy9V52 T cells and does not activate these cells comprises a CDR3 region, wherein the CDR3 region comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 3, 37, 40 and 43.

[0063] In another embodiment, the immunoglobulin molecule that does not block activation of human Vy9V52 T cells comprises a label.

[0064] Such immunoglobulin molecules are particularly useful for flow cytometric or immunohistochemical detection of cells expressing human Vy9V52 T cell receptors. The immunoglobulin molecules may comprise a tag, e.g. a myc-tag or his-tag or a fluorescent protein sequence as described in the examples, or may be conjugated to a suitable imaging dye. Furthermore, when conjugated to, e.g., magnetic beads, such immunoglobulin molecules can be used to isolate and purify these cells from cell suspensions, including cell suspensions from peripheral blood. These Vy9V52 T cell receptor binding immunoglobulin molecules may be developed as research tools for detection in immunohistochemistry, flow cytometry, imaging and for magnetic purification from cell suspensions. These immunoglobulin molecules have no effect on human Vy9V52 T cells, and are therefore particularly useful for selecting these cells for further use. Thus, the use of these immunoglobulin molecules for labeling or selecting human Vy9V52 T cells is further provided.

[0065] In another aspect of the invention there is provided an immunoglobulin molecule which is an immunoglobulin comprising a CDR1 region and a CDR2 region, wherein the CDR1 region comprises an amino acid sequence having at least 40% sequence identity with the amino acid sequence GRTFSNYAMG of SEQ ID NO: 31 and the CDR2 region comprises an amino acid sequence having at least 60% sequence identity with the amino acid sequence AISWSGGSTYYADSVKG of SEQ ID NO: 32, preferably a single chain antibody. T YY A DS VKG, said amino acid sequence having at least 60% sequence identity with said amino acid sequence having a T at position 9, an A at position 12 and a V at position 15. In another embodiment the immunoglobulin molecule is a single domain antibody, preferably the single domain antibody is a llama single chain antibody or a human single chain antibody. In another embodiment the single chain antibody is a single domain antibody. In another embodiment the immunoglobulin molecule or single chain antibody or single domain antibody comprises one or more framework regions selected from the group of amino acid sequences of SEQ ID NOs: 67-70. In another embodiment of this aspect of the invention the immunoglobulin molecule, single chain antibody or single domain antibody comprises a CDR3 region, the CDR3 region comprising an amino acid sequence selected from the group consisting of amino acid sequences SEQ ID NOs: 3, 6, 9, 11, 14, 17, 20, 22, 25, 27, 29, 30, 33, 35, 37, 40, 43 and 46.

[0066] In another aspect of the invention, there is provided an immunoglobulin molecule comprising a CDR3 region, wherein the CDR3 region comprises an amino acid sequence selected from the group consisting of amino acid sequences SEQ ID NOs: 3, 6, 9, 11, 14, 17, 20, 22, 25, 27, 29, 30, 33, 35, 37, 40, 43 and 46. EXAMPLES

[0067] Generation of donor-derived Vγ9Vδ2 T cells Healthy donor-derived (human) Vγ9Vδ2 T cells were generated and cultured as indicated (Schneiders FL et al., Clin Immunol 2012; 142: 194-200).

[0068] Generation of Jurkat Vγ9Vδ2 and Jurma Vγ9Vδ2 T cell lines Jurkat and Jurma cell lines expressing Vy9V52 TCR were synthesized according to previously described techniques (Scholten KB et al., Clin Immunol 2006; 119: 135-45). Briefly, the protein sequences of clone G9 Vy9 and V52 chains separated by a picornavirus-derived 2A sequence (Allison TJ et al., Nature 2001; 411: 820-4; Davodeau F et al., Eur J Immunol 1993; 23: 804-8) were codon modified for optimal protein production by GeneART (Life Technologies), synthesized, and then cloned into LZRS. After transfection into the Phoenix-A packaging cell line, retroviral supernatants were harvested and used to transduce Jurkat or Jurma cells.

[0069] Selection of anti-Vγ9Vδ2 TCR VHHs 2 llamas, 1×10 each 8Llama PBMCs were immunized four times with human donor-derived Vγ9Vδ2 T cells in sterile PBS over a period of six weeks. A phage library was constructed from extracted RNA isolated from llama PBMCs as indicated (Roovers RC et al. Cancer Immunol Immunother. 2007;56:303-17) and ligated into the phagemid vector pUR8100. VHHs specific for the Vγ9Vδ2 T cell receptor (TCR) were generated by two rounds of phage display selection. In the first round, phages from both libraries were incubated for 2 hours at 4°C with transduced Jurkat cells stably expressing the Vγ9Vδ2 TCR (Jurkat Vγ9Vδ2). After incubation, cells were washed and phages were eluted with 100 mM HCl. After 7 minutes of incubation at 4°C, unbound phages were removed and neutralized with Tris-HCl before infection with E. coli. After recovery of selected phages, the second round phages were first counterselected twice against Jurkat cells for 1 h at 4° C., after which unbound phages were incubated with Jurkat Vy9V52 for 1 h. Phages were eluted and infected into E. coli as indicated for the first round selection. Bacteria were plated on LB / 2% glucose / ampicillin plates to allow the formation of single bacterial colonies encoding the eluted VHH DNA.

[0070] Production and purification of VHHs VHH DNA from individual clones was digested with Sfi 1 / BstEII and cloned into plasmid pMEK219, a derivative of pHen1 (Hoogenboom et al., Nucleic Acids Res 1991) with the addition of an HC-V cassette to allow Sfi 1 / BstEII cloning and the removal of the C-terminal myc- and 6x HIS-tags of the genlll sequence. pMEK219-VHH was transformed into TG1 bacteria. An overnight culture was used to inoculate 2xTY medium supplemented with 0.1% glucose and 100ug / ml ampicillin. OD 6ooWhen the pH reached 0.5, IPTG was added to a final concentration of 1 mM. Protein production was allowed for 2–5 h. Growth of all cultures was performed at 37°C with shaking at 200–220 rpm. Protein production was stopped by spinning the cultures at 4°C for 15 min. Bacterial pellets were suspended in PBS and frozen for at least 1 h. Bacterial suspensions were thawed, shaken slightly at 4°C for 1 h and spun at 4500 rpm for 30 min. Supernatants were incubated with washed Talon resin (Clontech, 1290 Terra Bella Avenue, Mountain View, CA, USA) for 1 h at room temperature. Talon resin was washed three times with PBS and once with 15 mM imidazole / PBS pH 7 and eluted with 150 mM imidazole / PBS pH 7. The eluted fraction was dialyzed twice against PBS. Purity of purified VHHs was confirmed by Coomassie stained protein gel.

[0071] Binding of VHHs to donor-derived Vγ9Vδ2 T cells or Jurkat Vγ9Vδ2 T cells. 5×10 4 donor-derived Vγ9Vδ2 T cells were washed with FACS buffer. All incubations were performed for 30 min at 4°C in FACS buffer. Cells were incubated with 25 μl of 500 nM VHH. After washing, cells were incubated with 10 μl of 1:500 anti-myc tag antibody clone 4A6 (Merck Millipore, 290 Concord Road, Billerica, MA, USA). After washing, cells were incubated with 10 μl of 1:200 goat anti-mouse F(ab)2 APC (Beckman Coulter, Fullerton, CA, USA) for 30 min at 4°C. After a final washing step, binding of VHH to cells was measured by flow cytometry (FACSCalibur, BD Biosciences).

[0072] Activation of donor-derived Vγ9Vδ2 T cells by VHHs Flat bottom 96-well cell culture plates (Costar) were coated overnight at 4°C with 50μl of 4ug / ml mouse anti-myc clone 9E10 (made in-house). Wells were washed with PBS and blocked with 200μl of 4% BSA / PBS for 30 minutes at room temperature. The block was discarded and wells were incubated with 500nM VHH in 30μl PBS for 2 hours at room temperature. Wells were washed and 1x10 mAbs in IMDM+ was added per well in 200μl. 4 Vγ9Vδ2 T cells (Schneiders FL et al., Clin Immunol 2012; 142: 194-200) were added and incubated overnight at 37°C in a CO2 incubator with a humidified atmosphere in the presence of golgiplug (1:500) (BD Biosciences) for intracellular cytokine retention. CD25, IFN-γ and Granzyme B expression was then measured using flow cytometry {as described below; Schneiders FL et al., Clin Immunol 2012; 142: 194-200 [CD25-PE (clone M-A251, no. 555432), IFN-γ APC (clone B27 no. 554702) both available from BD Pharmingen. Granzyme B PE (clone GB-12 no. M2289) available from Sanquin, Amsterdam, The Netherlands]}.

[0073] Neutralization of donor-derived Vγ9Vδ2 T cells by VHHs HeLa cells were incubated with the indicated amounts of aminobisphosphonate (NBP; ABP disodium pamidronate, Pharmachemie, Haarlem, The Netherlands) for 2 h at 37 °C in a CO2 incubator with a humidified atmosphere. Afterwards, cells were washed and plated in 5 × 10 cells in 100 μl of IMDM+ per well of a flat-bottom 96-well cell culture plate (Costar). 4Cells were plated at 75 × 10 and allowed to attach for 2 h at 37 °C in a CO2 incubator with a humidified atmosphere. Cells were washed with PBS and cultured in 100 μl IMDM+. Donor-derived Vγ9Vδ2 T cells were incubated with the indicated VHH concentrations for 1 h at 4 °C. 3 VHH-incubated Vγ9Vδ2 T cells were added to wells coated with NBP-treated HeLa cells and incubated at 37°C in a CO2 incubator with a humidified atmosphere. Cells were harvested into 96-well round-bottom plates using trypsin and Golgiplug (1:500, BD Biosciences) was added for intracellular cytokine retention. CD25, IFN-γ and Granzyme B expression was measured using flow cytometry (as described below; Schneiders FL et al., Clin Immunol 2012; 142: 194-200).

[0074] VHH chain specificity Donor-derived Vy9V52 T cell lines were stained with mouse anti-human V52-FITC and mouse anti-human Vy9-PE (both BD Biosciences) and sorted on a FACS Aria (BD Biosciences) for the following populations: V52 single positive γδ T cells, Vy9 single positive γδ T cells, Vy9V52 double positive γδ T cells and Vy9V52 double negative γδ T cells. Sorted cells were cultured in the same way as donor-derived Vy9V52 T cell lines. To determine the specificity of VHHs, 10 4 The resulting purified sorted cell lines of cells were stained with VHHs similar to the methodology described for VHH binding to donor-derived Vy9V52 T cells, with the adjustment that 10 μl of 1:80 goat anti-mouse-F(ab)2 RPE (Dako no. R0480, Glostrup, Denmark) was used for detection of anti-myc antibodies.

[0075] result The selected VHHs were tested for specificity as described above and all 20 VHHs (see Table 2) showed binding to Jurkat cells expressing the Vy9V52 T cell receptor as well as primary Vy9V52 T cells, but not to Jurkat cells not expressing the Vy9V52 T cell receptor.

[0076] Immunoglobulin molecules that block phosphoantigen-induced activation Clones 6F6 and 5E7 were characterized as nanobodies that block phosphoantigen-induced stimulation of Vy9V52 T cells. Both clones 6F6 and 5E7 are nanobodies that bind to the V52 chain of the Vy9V52 T cell receptor. Expression of GrB, CD25 and IFN-gamma was similar to the unstimulated control, whereas the positive control showed relatively high expression levels (see FIG. 2). Dose-response curves show a dose-dependent neutralization of phosphoantigen-induced Vy9V52 T cell activation upon exposure to phosphoantigen (see FIG. 3). It was further shown that the VHH 5E7 nanobody inhibited aminobisphosphonate (ABP)-induced Vy9V52 T cell activation in a dose-dependent manner. That is, higher doses of 5E7 caused a relatively significant reduction in CD25 and CD107a expression, as well as in interferon-gamma and TNF-alpha production. It was also shown that the 5E7 nanobody inhibited the spontaneous lysis of Daudi cells by Vγ9Vδ2 T cells in a dose-dependent manner, whereas the control nanobody did not show any significant effect. In the same assay, the use of the nitrogen-containing bisphosphonate, pamidronate, to activate Vγ9Vδ2 T cells resulted in improved lysis of Daudi cells. On the other hand, the 5E7 nanobody reduced the lysis of Daudi cells in a dose-dependent manner. This indicates that any undesired activation of Vγ9Vδ2 T cells can be reduced by using nanobodies that block Vγ9Vδ2 T cell activation. Such antibodies that block Vγ9Vδ2 T cell activation may be antibodies that bind to the Vδ2 chain of the Vγ9Vδ2 T cell receptor.

[0077] Activation-inducing immunoglobulin molecules Various VHHs were shown to activate Vy9V52 T cells as shown by increased CD25 expression and increased IFN-gamma expression (see Figure 4). Moreover, such VHHs showed a typical dose response, since increasing doses of VHHs also increased CD25 expression (see Figure 5, right panel). Such VHHs were also linked to immunoglobulin molecules and their effect on tumor cell apoptosis was investigated (see Figure 6). Bispecific VHHs (anti-cancer cell binding and Vy9V52 T cell binding and activation) showed potent activity towards killing tumor cells. Bispecific VHHs were generated by linking the anti-Vy9V52 nanobody 6H4 with a nanobody against tumor. As bispecific controls, the anti-Vy9V52 nanobody was linked with a control nanobody and the anti-tumor nanobody was linked with a control nanobody. At the highest dose tested (10 nM), only the control caused lysis of about 22% of tumor cells. Bispecific VHHs (or nanobodies) binding both to Vy9V52 T cells and tumor cells caused about 85% tumor cell lysis mediated by Vy9V52 T cells. In dose-response curves, the percentage of lysis by Vy9V52 T cells decreased with lower doses (about 80% at 1 nM, about 78% at 100 pM, about 50% at 10 pM, about 23% at 1 pM and about 24% at 0). In control experiments using only bisphosphonates without (bispecific) nanobodies, about 80% tumor cell lysis was observed. These results show that tumor-specific lysis by Vy9V52 T cells can be improved by using bispecific VHHs (or nanobodies), where both tumor cells and Vy9V52 T cells are targeted, and specific tumor targeting of Vy9V52 T cells also induces activation of Vy9V52 T cells.

[0078] Immunoglobulin molecules that do not induce activation or block phosphoantigen activation Several VHHs (5D7, 5C7, 5B11 and 6C4) showed no activation of human Vy9V52 T cells and were ineffective in blocking phosphoantigen-mediated activation of human Vy9V52 T cells (Figure 8 and Figure 5, left panel). Such VHHs are useful, for example, for FACS sorting (see Figure 7).

[0079] Magnetic Bead Separation Anti-V52 (e.g., 6H4) or Vy9 nanobodies (e.g., 6H1) were biotinylated and mixed with PBMCs. The cells were washed to remove unbound nanobodies. Streptavidin-bearing magnetic beads (such as those available from Miltenyi Biotec) were added to the mixture and cells bound to the beads via the biotinylated nanobodies were separated from unbound cells using a magnetic separating column. PBMCs were FACS analyzed for Vy9 and V52 expression. Both anti-V52 and Vy9 nanobodies gave very good purification. For example, with nanobody 6H4, 4.5% of PBMCs expressed both chains and after magnetic bead separation, 97.4% of cells were positive for both Vy9 and V52 chains. The fraction of cells that did not bind to the magnetic beads was negative for both Vy9 and V52 chains (0%).

[0080] [Table 2]

[0081] [Table 3A] [Table 3B] [Table 3C] [Table 3D] [Table 3E]

Table 3F

Claims

1. 1. A bispecific immunoglobulin molecule comprising a single domain antibody (VHH) comprising a CDR1 region, a CDR2 region, and a CDR3 region, which activates human Vγ9Vδ2 T cells and binds to the Vδ2 chain of a Vγ9Vδ2 receptor, wherein said CDR1 region comprises SEQ ID NO: 18, said CDR2 region comprises SEQ ID NO: 19, and said CDR3 region comprises SEQ ID NO: 20, and wherein said bispecific immunoglobulin molecule further comprises a tumor antigen-specific antibody.

2. 2. The bispecific immunoglobulin molecule of claim 1, wherein said single domain antibody (VHH) that activates human Vγ9Vδ2 T cells and binds to the Vδ2 chain of the Vγ9Vδ2 receptor comprises the amino acid sequence of SEQ ID NO:

54.

3. 3. The bispecific immunoglobulin molecule of claim 1 or 2, wherein the antibody that activates human Vγ9Vδ2 T cells is a single chain antibody.

4. The bispecific immunoglobulin molecule of any one of claims 1 to 3, wherein said tumor antigen-specific antibody is a single domain antibody (VHH).

5. 5. The bispecific immunoglobulin molecule of any one of claims 1 to 4, wherein said single domain antibody that activates human Vγ9Vδ2 T cells binds to Vγ9Vδ2 double positive T cells and Vδ2 single positive T cells but does not bind to Vγ9 single positive T cells.

6. The bispecific immunoglobulin molecule of any one of claims 1 to 5, wherein the tumor antigen-specific antibody is a single chain antibody.

7. (a) a single chain antibody comprising a CDR1 region of SEQ ID NO: 18, a CDR2 region of SEQ ID NO: 19, and a CDR3 region of SEQ ID NO: 20; and (b) A tumor antigen-specific antibody that is a single chain.

7. The bispecific immunoglobulin molecule of claim 1 , comprising:

8. 8. The bispecific immunoglobulin molecule of claim 7 , wherein each of the single chain antibodies (a) and (b) is of the IgG1 isotype.

9. A cancer therapeutic agent comprising the bispecific immunoglobulin molecule of any one of claims 1 to 8.

10. A medical composition for the treatment of cancer comprising a bispecific immunoglobulin molecule according to any one of claims 1 to 8.

11. A nucleotide sequence encoding a bispecific immunoglobulin molecule according to any one of claims 1 to 8.

12. A host cell comprising a polynucleotide encoding the bispecific immunoglobulin molecule of any one of claims 1 to 8.

13. A method for preparing a bispecific immunoglobulin molecule according to any one of claims 1 to 8, - culturing a host cell according to claim 12; - expressing said bispecific immunoglobulin in said host cell; - obtaining said bispecific immunoglobulin; A method comprising: